ADAR1 Capital Management »

2seventy Bio shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of 2seventy Bio (TSVT) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in 2seventy Bio

Tip: Access up to 7 years of quarterly data

All positions including 2seventy Bio held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in 2seventy Bio by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $4.3k 1.0k 4.27

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Roivant Sciences SHS (ROIV)
Cytokinetics Com New (CYTK)
Arbutus Biopharma (ABUS)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Cerevel Therapeutics Hldng I (CERE)
Mirati Therapeutics
Merck & Co (MRK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Immunovant (IMVT)
Viking Therapeutics (VKTX)
Protagonist Therapeutics (PTGX)

View all positions for ADAR1 Capital Management

Top funds holding 2seventy Bio

Kynam Capital Management
Goldman Sachs Group
Vanguard Group
Baker Bros. Advisors
Millennium Management
Madison Avenue Partners
DAFNA Capital Management
Casdin Capital
Marshall Wace
Jpmorgan Chase & Co
Cowen And Company
Charles Schwab Investment Management
Wellington Management Company
Point72 Asset Management
AQR Capital Management

View all funds holding 2seventy Bio